Co-Inventors
Nishimura, Yoshiaki
Shingai, Masashi
Gautam, Rajeev
Sadjadpour, Reza
Therapeutic Areas
Rare/Neglected Diseases
Infectious Disease
Immunology
Research Products
Research Equipment
Plasmids/Vectors
The discovery involves the development and characterization of a novel SHIVAD8EO virus, which has significant implications for HIV/AIDS research and therapy development. This virus, when propagated in DH101 cells and used to infect rhesus PBMC, exhibits efficient replicative properties and utilizes CCR5 to enter monkey cells. Importantly, the virus displays a tier 2 neutralization phenotype similar to circulating HIV-1 strains. In vivo studies have shown that SHIVAD8EO can generate sustained levels of plasma viremia, cause irreversible depletions of CD4+ T cells, induce fatal immunodeficiency, and resist certain treatments. These properties make SHIVAD8EO a valuable tool for studying HIV/AIDS pathogenesis and for evaluating new therapeutic approaches. This discovery is documented in lab records and has been described in a publication in the Proceedings of the National Academy of Sciences.
Commercial Applications
The novel SHIVAD8EO virus has a wide range of potential applications in HIV/AIDS research and therapy development. As a robust model that closely mimics the properties of circulating HIV-1 strains, SHIVAD8EO can be used to study various aspects of HIV/AIDS pathogenesis, including viral replication, immune response, and disease progression. Additionally, its ability to generate sustained levels of plasma viremia and induce fatal immunodeficiency in vivo makes it a valuable tool for evaluating the efficacy of new antiretroviral drugs and immunotherapies. SHIVAD8EO can also be utilized to investigate viral reservoirs and the mechanisms of viral persistence, which are critical areas of research for developing strategies to achieve HIV cure or long-term remission. Furthermore, SHIVAD8EO may be instrumental in the development and testing of novel HIV vaccines, providing a realistic model for evaluating vaccine candidates. Overall, the versatility and relevance of SHIVAD8EO make it a valuable resource for advancing HIV/AIDS research and therapeutic interventions.
Competitive Advantages
The novel SHIVAD8EO virus offers several key competitive advantages over existing models and technologies in HIV/AIDS research. Its efficient replicative properties, utilization of CCR5 for cell entry, and tier 2 neutralization phenotype closely mimic those of circulating HIV-1 strains, providing a more accurate model for studying HIV/AIDS pathogenesis and evaluating potential therapies. Importantly, SHIVAD8EO's ability to generate sustained levels of plasma viremia, induce fatal immunodeficiency, and resist certain treatments in vivo make it a valuable tool for preclinical studies. These unique characteristics set SHIVAD8EO apart from other models and technologies, offering researchers a more reliable and relevant platform for advancing our understanding of HIV/AIDS and developing novel treatment strategies.
